Biomaxima (WAR:BMX) — Stock Price
Biomaxima (WAR:BMX) is currently trading at zł10.02 PLN, down 0.60% today. Over the past 52 weeks, shares have ranged between zł9.30 and zł14.25. This page tracks Biomaxima's live share price on the WAR exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Biomaxima market capitalisation.
Biomaxima (BMX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Biomaxima's daily closing share price and trading volume on the WAR exchange over the past year, giving a clear view of recent price momentum and liquidity.
Biomaxima Income Statement — Revenue, Profit & Earnings by Year
Biomaxima's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | zł52.85 Million | zł46.79 Million | zł143.87 Million | zł79.09 Million | zł61.61 Million |
| Cost of Revenue | zł29.59 Million | zł26.76 Million | zł89.64 Million | zł50.09 Million | zł37.76 Million |
| Gross Profit | zł23.26 Million | zł20.02 Million | zł54.23 Million | zł28.99 Million | zł23.85 Million |
| Research & Development | — | — | — | — | — |
| SG&A | — | — | — | zł4.72 Million | zł3.15 Million |
| Total Operating Expenses | zł21.95 Million | zł20.95 Million | zł19.38 Million | zł15.40 Million | zł13.07 Million |
| Operating Income | zł1.31 Million | zł728.00K | zł34.85 Million | zł13.65 Million | zł10.47 Million |
| EBITDA | zł4.65 Million | zł3.28 Million | zł38.36 Million | zł14.78 Million | zł11.41 Million |
| EBIT | zł1.28 Million | zł796.00K | zł36.34 Million | zł13.04 Million | zł9.93 Million |
| Interest Expense | zł978.00K | zł609.00K | zł475.00K | zł262.00K | zł364.00K |
| Income Before Tax | zł306.00K | zł187.00K | zł35.87 Million | zł12.78 Million | zł9.57 Million |
| Income Tax Expense | zł-229.00K | zł-399.00K | zł6.98 Million | zł2.53 Million | zł1.62 Million |
| Net Income | zł535.00K | zł586.00K | zł28.89 Million | zł10.24 Million | zł7.95 Million |
Biomaxima Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Biomaxima's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | zł76.34 Million | zł73.78 Million | zł74.42 Million | zł61.93 Million | zł53.43 Million |
| Total Current Assets | zł25.44 Million | zł22.83 Million | zł36.23 Million | zł33.55 Million | zł25.38 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | zł13.00K | zł13.00K | zł13.00K |
| Net Receivables | zł11.01 Million | zł7.09 Million | zł10.08 Million | zł15.98 Million | zł6.77 Million |
| Inventory | zł13.52 Million | zł12.77 Million | zł12.82 Million | zł14.02 Million | zł12.43 Million |
| Property, Plant & Equipment | — | — | — | zł27.87 Million | zł21.71 Million |
| Goodwill | zł0.00 | zł0.00 | zł0.00 | zł0.00 | zł271.59K |
| Total Liabilities | zł29.01 Million | zł26.81 Million | zł21.96 Million | zł32.74 Million | zł27.49 Million |
| Total Current Liabilities | zł17.14 Million | zł10.44 Million | zł10.98 Million | zł17.35 Million | zł13.09 Million |
| Long-term Debt | zł5.24 Million | zł8.61 Million | zł3.86 Million | zł8.02 Million | zł7.09 Million |
| Net Debt | zł13.71 Million | zł11.36 Million | zł-7.08 Million | zł16.96 Million | zł7.16 Million |
| Total Stockholder Equity | zł47.33 Million | zł46.97 Million | zł52.46 Million | zł29.19 Million | zł19.89 Million |
| Retained Earnings | zł33.18 Million | zł32.84 Million | zł34.18 Million | zł12.24 Million | zł3.08 Million |
Biomaxima Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Biomaxima generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | zł-152.00K | zł1.59 Million | zł37.06 Million | zł-132.00K | zł3.97 Million |
| Capital Expenditures | zł2.27 Million | zł18.08 Million | zł9.88 Million | zł4.48 Million | zł1.88 Million |
| Free Cash Flow | zł-2.42 Million | zł-16.49 Million | zł27.19 Million | zł-4.61 Million | zł2.09 Million |
| Investing Cash Flow | zł-759.00K | zł-17.25 Million | zł-7.83 Million | zł-3.37 Million | zł-1.65 Million |
| Financing Cash Flow | zł317.00K | zł4.25 Million | zł-19.32 Million | zł2.11 Million | zł1.48 Million |
| Dividends Paid | — | zł2.10 Million | zł1.95 Million | zł1.10 Million | zł1.10 Million |
| Stock-Based Compensation | — | zł0.00 | zł0.00 | zł133.00K | zł182.00K |
| Depreciation | zł3.36 Million | zł2.49 Million | zł2.02 Million | zł1.65 Million | zł1.89 Million |
| Change in Cash | zł-594.00K | zł-11.40 Million | zł9.91 Million | zł-1.39 Million | zł3.80 Million |
Biomaxima Earnings History — EPS Actual vs. Analyst Estimates
Track Biomaxima's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 30, 2025 | -0.07 | — | — |
| Jun 30, 2025 | -0.14 | — | — |
| May 30, 2025 | 0.14 | — | — |
| Dec 31, 2024 | 0.23 | — | — |
| Sep 30, 2024 | -0.06 | — | — |
| Jun 30, 2024 | -0.10 | — | — |
| May 29, 2024 | 0.06 | — | — |
| Dec 31, 2023 | 0.02 | — | — |